Bloch Yuval, Vardi Osnat, Mendlovic Shlomo, Levkovitz Yechiel, Gothelf Doron, Ratzoni Gideon
Shalvata Mental Health Center, Hod Hasharon, PO Box 94, Israel.
J Child Adolesc Psychopharmacol. 2003 Spring;13(1):97-102. doi: 10.1089/104454603321666234.
The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain. Of the reports of glucose dysregulation related to olanzapine therapy, only a few pertain to adolescents. We present five cases: two youths who consequently suffered from overt diabetes and three who responded with glucose dysregulation. According to the Naranjo probability scale, the relation of this phenomenon to olanzapine therapy is "probable." We consider the findings of the presented case series as justification for regular metabolic follow-up for apparently healthy adolescents receiving olanzapine therapy.
奥氮平在青少年患者治疗中的使用日益增加，这使得人们对该药物已确认的副作用，尤其是体重增加，有了更高的认识。在与奥氮平治疗相关的血糖调节异常报告中，仅有少数涉及青少年。我们呈现五例病例：两例青少年最终患上显性糖尿病，三例出现血糖调节异常。根据纳伦霍概率量表，这一现象与奥氮平治疗之间的关系为“很可能”。我们认为，所呈现的这组病例的研究结果足以作为对接受奥氮平治疗的表面健康青少年进行定期代谢随访的依据。
